COMMUNIQUÉS West-GlobeNewswire

Announcement of share buyback program
19/08/2026
The Board of Directors of Novonesis has approved an inaugural multi-year share buyback program in a total amount of EUR 1 billion to be initiated during the second half of 2026 and expected to be completed by the end of [...]
Interim report H1 2026
19/08/2026
Strong first half year at 8% organic sales growth. 2026 outlook: Organic sales growth increased to 7-8% and the adjusted EBITDA margin expected at the higher end of the 37-38% range. Inaugural share buy-back program [...]
H1 2026: Novonesis delivered strong 8% organic sales growth and increases full-year outlook
19/08/2026
COPENHAGEN, Denmark – August 19, 2026. Novonesis delivered strong first half of 2026 at 8% organic sales growth. 2026 outlook: Organic sales growth increased to 7-8% (previously 5-7%), and the adjusted EBITDA margin [...]
Interim Report Q2 2026: Successful reception of Evolve3 headsets and gross margin improvement boding well for strong H2 2026
19/08/2026
Highlights The Enterprise division delivered organic revenue growth of -7%, while the organic revenue growth excl. FalCom ended at -3%. The development reflects continued strong growth in North America and APAC. The [...]
Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial in Adults with Fibrodysplasia Ossificans Progressiva (FOP)
19/08/2026
FOP is an ultra-rare genetic disorder characterized by rogue bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability Approval based on results from [...]
Sofwave Surpasses One Million Treatments Worldwide; Milestone Treatment Performed in South Korea
19/08/2026
Global milestone reflects sustained physician utilization, patient adoption and the expanding reach of Sofwave’s SUPERB™ technology SAN CLEMENTE, Calif., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd. (TASE: [...]
Atsena Therapeutics Appoints Matt Pauls to Board of Directors
19/08/2026
Matt Pauls brings more than 25 years of biopharma leadership and rare disease clinical development and commercial expertise as Atsena advances its ocular gene therapy pipeline toward commercialization DURHAM, N.C., Aug [...]
Humacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results
19/08/2026
– Phase 3 results highlight benefits of ATEV for patients at higher risk of fistula failure, including all women and men with obesity and diabetes – – Publication provides peer-reviewed validation for V007 Phase 3 data [...]
Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD – The Liver Meeting® 2026
19/08/2026
WILMETTE, Ill., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with [...]
AEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX®
19/08/2026
- Complementary peptide-mapping methods increased coverage of the active botulinum neurotoxin primary sequence from approximately 93% to 98%, with 100% amino acid identity across all regions analyzed - Preliminary [...]
MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies
19/08/2026
ROCKVILLE, Md., Aug. 19, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and [...]
Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update
19/08/2026
Proposed merger with Scipher Medicine to assess nebokitug in a Phase 2 precision medicine trial in rheumatoid arthritis (RA) continues to advance with closing expected by year-end RA is a $24 billion market with [...]
Intelligent Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth of 38% Year-over-Year, Driven by Reader Installed Base and High-Margin Cartridge Growth
19/08/2026
Reader installed base grew 22% year-over-year, driving a 35% increase in total consumable cartridges to over 100,000 units Full year gross profit margin expanded to 48.63%, up 778 basis points year-over-year 502 active [...]
NOMAD Achieves UL 9540 Certification for 1 MW Transportable Battery Energy Storage System
19/08/2026
Certified Traveler system supports resilient power deployment for Missanabie Cree First Nation in Northern Ontario, Canada BOCA RATON, Fla., Aug. 19, 2026 (GLOBE NEWSWIRE) -- NOMAD Power Solutions Inc. ("NOMAD" or the " [...]
U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome
19/08/2026
Ecopipam (EBS-101) is a first-in-class selective D1 (dopamine) receptor antagonist with Orphan Drug designation NDA acceptance is supported by positive Phase 3 data, which were published in JAMA Neurology, and Phase 2b [...]
Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP
19/08/2026
August 19, 2026 Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP 87 subjects, over 50% of target, recruited Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “the Company”), a [...]
Earth Science Tech, Inc. (ETST) Acquires Zoolzy LLC to Drive Margin Expansion and Strategic Entry into the Veterinary Market
19/08/2026
MIAMI, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) (“ETST” or the “Company”), a strategic holding company focused on a diversified portfolio, today announced the acquisition of Zoolzy LLC, a [...]
Regional Health Properties Reports Second Quarter 2026 Results
19/08/2026
.Reported Second Quarter Revenue of $24.4 million Generated Adjusted EBITDA from Operations of $0.7 million Continued Execution of Integrated Healthcare Platform Strategy ATLANTA, GA, Aug. 19, 2026 (GLOBE NEWSWIRE) -- [...]
InterCure Ltd. Announces 1-for-5 Reverse Share Split
19/08/2026
Strategic Action Aimed at Regaining Compliance with Nasdaq’s Minimum Bid Price Requirement and Protecting Continued Listing Status NEW YORK and HERTZLIYA, ISRAEL, Aug. 19, 2026 (GLOBE NEWSWIRE) -- InterCure Ltd. (the “ [...]

Pages